MedTrace Logo

Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

NCT02843074 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2023-12-05

Study results available
· View outcomes & findings →

Summary

This is a phase 2, single arm, open-label, multicenter study to evaluate the feasibility and tolerance of the combination of elotuzumab, lenalidomide, and dexamethasone in the induction, consolidation, and maintenance treatment of transplant eligible, newly diagnosed multiple myeloma patients.

Conditions

Interventions

DRUG

elotuzumab

Given intravenously (IV)

DRUG

Lenalidomide

Given by IV

DRUG

Dexamethasone

Given orally (PO) or by IV

PROCEDURE

autologous stem cell transplantation

Sponsors & Collaborators

Principal Investigators

  • Jesus Berdeja, MD · SCRI Development Innovations, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-21
Primary Completion
2021-07-27
Completion
2021-10-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02843074 on ClinicalTrials.gov